Tadalafil
- Generic Name
- Tadalafil
- Brand Names
- Adcirca, Alyq, Cialis, Entadfi, Tadliq, Talmanco (previously Tadalafil Generics), Tadalafil Mylan, Tadalafil Lilly, Adcirca (previously Tadalafil Lilly)
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19N3O4
- CAS Number
- 171596-29-5
- Unique Ingredient Identifier
- 742SXX0ICT
- Background
Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy. It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibitors like sildenafil, tadalafil has greater selectivity for PDE5 and a longer half-life which has made it a more suitable option for chronic once-daily dosing in the treatment of PAH.
- Indication
Tadalafil is indicated for the treatment of erectile dysfunction (ED) and either alone or in combination with finasteride for the treatment of benign prostatic hypertrophy (BPH). It is also indicated for the treatment of pulmonary arterial hypertension (PAH) both alone and in combination with macitentan or other endothelin-1 antagonists.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Erectile Dysfunction, Pulmonary Arterial Hypertension (PAH)
Clinical Investigation Using MED3000 Gel or Tadalafil Tablets in the Treatment of Erectile Dysfunction
- Conditions
- Erectile Dysfunction
- Interventions
- Device: MED3000 (Male)Device: MED3000 (Female)
- First Posted Date
- 2021-08-02
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Futura Medical Developments Ltd.
- Target Recruit Count
- 116
- Registration Number
- NCT04984993
- Locations
- 🇵🇱
Provita Sp. z o.o., Katowice, Poland
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇧🇬Medical Center "Asklepii"OOD, Dupnitsa, Bulgaria
Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Dongkook Pharmaceutical Co., Ltd.
- Target Recruit Count
- 667
- Registration Number
- NCT04947631
- Locations
- 🇰🇷
Ewha Womans University mokdong Hospital, Seoul, Korea, Republic of
The Use of Tadalafil in Confirmed COVID-19 Pneumonia.
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Santa Barbara Cottage Hospital
- Registration Number
- NCT04946162
A Single Dose Randomized Five-Way Crossover Pharmacokinetics (PK) Study of Tadalafil Semi-Chewable (Gummy) Formulations in Healthy Volunteers
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Seattle Gummy Company
- Target Recruit Count
- 30
- Registration Number
- NCT04762082
Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma
- Conditions
- Astrocytoma, Grade IIIGrade IV AstrocytomaGrade III AstrocytomaAstrocytoma, Grade IV
- Interventions
- First Posted Date
- 2021-02-17
- Last Posted Date
- 2023-06-13
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 18
- Registration Number
- NCT04757662
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Effectiveness and Tolerability of the On-demand Use of Combined Dapoxetine With Tadalafil and Combined Dapoxetine With Lidocaine 5% Spray in Treatment of Patients With Lifelong Premature Ejaculation and Non-responding to Dapoxetine Alone.
- Conditions
- Premature Ejaculation
- Interventions
- Drug: Dapoxietine and Combined Lidocaine 5% Spray
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Sohag University
- Target Recruit Count
- 60
- Registration Number
- NCT04703127
- Locations
- 🇪🇬
Mohammed Abu El-Hamd, Sohag, Egypt
Effect of PDE5 Inhibition on Adipose Metabolism in Humans
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT04684589
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Comparative Study Between Tadalafil Versus Tamsulosin as a Medical Expulsive Therapy for Lower Ureteric Stones
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- Beni-Suef University
- Target Recruit Count
- 166
- Registration Number
- NCT04641507
- Locations
- 🇪🇬
Ahmed Saleh, Giza, Egypt
Combined Effect of Continuous and Interval in Addition to Tadalafil Drug on Erectile Dysfunction
- Conditions
- Erectile Dysfunction
- Interventions
- Other: Tadalafil 5Mg Tab + continuous and interval exercise
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 60
- Registration Number
- NCT04623840
- Locations
- 🇪🇬
Cairo Unoversity, Giza, Egypt
Safety and Efficacy of Tadalafil vs. Tadalafil With Sildosin in the Management of Moderately and Severely Symptomatic Patients of Prostatic Hyperplasia
- Conditions
- Safety and Efficacy of Tadalafil vs. Tadalafil With Sildosin in the Management of Moderately and Severely Symptomatic Patients of Prostatic Hyperplasia
- Interventions
- First Posted Date
- 2020-10-06
- Last Posted Date
- 2020-10-06
- Lead Sponsor
- Menoufia University
- Target Recruit Count
- 400
- Registration Number
- NCT04577040
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.